| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10908990 | Leukemia Research | 2014 | 9 Pages |
Abstract
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p = 0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p = 0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lisa Pleyer, Ulrich Germing, Wolfgang R. Sperr, Werner Linkesch, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Martin Schreder, Michael Pfeilstocker, Alois Lang, Thamer Sliwa, Dietmar Geissler, Konstantin Schlick, Gudrun Placher-Sorko,